Striving for certainty when delivering a diagnosis.
When looking for ways to make more informed, data-driven decisions, companion diagnostics present a promising way forward for personalized healthcare. Using well-designed assays that run on easy-to-use automated systems, you can reduce errors caused by manual handling and streamline overall workflows while decreasing the number of tests needed to identify patients appropriate for various treatment options.
The VENTANA PD-L1 (SP263) Assay is tested on patient samples against a growing range of tumor types to determine who is most likely to respond to specific therapies.
These are the top 10 reasons the expanding application of this predictive assay is ideal for future-focused labs looking for a sustainable PD-L1 diagnostic solution.